Clinical Trials Logo

Clinical Trial Summary

Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C]AZD2423 in healthy male volunteers aged 50 to 65 years (inclusive).The purpose of this study is to investigate how and how quickly AZD 2423 or its break down products are excreted by analysing blood, faeces and urine samples collected during the study.


Clinical Trial Description

n/a


Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01223014
Study type Observational
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date November 2010
Completion date December 2010

See also
  Status Clinical Trial Phase
Recruiting NCT05201534 - Interventions in Mathematics and Cognitive Skills N/A
Not yet recruiting NCT03998787 - Metabotropic Receptors For Glutamate Type 3 In Parkinson's
Completed NCT03324217 - Effects of Motor Imagery and Action Observation on Electromyographic Activity and Intramuscular Oxygenation in the Hand Gripping Gesture N/A
Recruiting NCT06264063 - Study of Behavioral Dysfunctions and Related Neuronal Correlates in Patients With Dystonia N/A
Not yet recruiting NCT03781557 - Effects of Omega-3 Fatty Acids Supplement in Cognition of Young Healthy Adults and in Their Reaction Time of Computerized Test After 3 Months of Taking High-concentrated DHA and EPA Fish Softgels Phase 4
Recruiting NCT06251479 - Study of the Dynamics of Verbal and Non-verbal Interaction in Healthy Subjects, Through the Recording of Body Movements and Non-invasive Neurophysiological Techniques N/A
Recruiting NCT05084300 - Effectiveness Pain Neuroscience Education In The Executive Functions In Patients With Fibromyalgia N/A